ClinVar Miner

Submissions for variant NM_206965.2(FTCD):c.1358C>T (p.Thr453Met)

gnomAD frequency: 0.00075  dbSNP: rs200283734
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Baylor Genetics RCV000191087 SCV000245483 uncertain significance Glutamate formiminotransferase deficiency criteria provided, single submitter clinical testing
Invitae RCV000191087 SCV000820206 uncertain significance Glutamate formiminotransferase deficiency 2022-09-19 criteria provided, single submitter clinical testing This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 453 of the FTCD protein (p.Thr453Met). This variant is present in population databases (rs200283734, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with FTCD-related conditions. ClinVar contains an entry for this variant (Variation ID: 209155). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FTCD protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002517909 SCV003598530 uncertain significance Inborn genetic diseases 2021-02-22 criteria provided, single submitter clinical testing The c.1358C>T (p.T453M) alteration is located in exon 12 (coding exon 12) of the FTCD gene. This alteration results from a C to T substitution at nucleotide position 1358, causing the threonine (T) at amino acid position 453 to be replaced by a methionine (M). The p.T453M alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
CeGaT Center for Human Genetics Tuebingen RCV003436983 SCV004151975 likely benign not provided 2024-01-01 criteria provided, single submitter clinical testing FTCD: BP4
Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille RCV001251767 SCV001427509 uncertain significance Intellectual disability 2019-01-01 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.